Immunohematological dilemma due to daratumumab!
6th Global Summit on Allergy and Immunology & 6th International Conference on Clinical Hematology & Transfusion Medicine & 4th World Congress on Infection Prevention and Control & 2nd European Congress on Virology and Immunology
April 29, 2022 | Joint Webinar
Kokilaben Dhirubhai Ambani Hospital, India
Posters & Accepted Abstracts : Microbiology: Current Research
CD38 is a disulfide???linked molecule present on red blood cells (RBCs) and daratumumab; an anti???CD38 monoclonal antibody is a novel agent for treating multiple myeloma patients. Now-a-days it is also being explored to treat many other oncology conditions. The presence of daratumumab in the sera can interfere with immunohematological testing performed as a part of the pretransfusion testing protocols. Interferences can lead to a variety of challenging situations like – blood group discrepancy, mimicking high titre low avidity antibody (HTLA), incompatibility issues during compatibility testing, demonstrating auto/allo – antibody like pattern etc. We would like to present here a case of relapsed multiple myeloma post-autologous hematopoietic stem cell transplant who presented to our department with ABO blood group discrepancy and a positive antibody screen due to the interference of his past treatment with daratumumab. This case further emphasizes the fact that effective communication between blood transfusion services and oncology departments are crucial in the timely resolution of daratumumab interferences even after its course has been completed.